These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26014624)

  • 1. Vortioxetine.
    Australas Psychiatry; 2015 Jun; 23(3):306, 315. PubMed ID: 26014624
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?
    Keks NA; Hope J; Culhane C
    Australas Psychiatry; 2015 Jun; 23(3):210-3. PubMed ID: 25907797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
    He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
    J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
    Zhang J; Mathis MV; Sellers JW; Kordzakhia G; Jackson AJ; Dow A; Yang P; Fossom L; Zhu H; Patel H; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Jan; 76(1):8-14. PubMed ID: 25562777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder.
    Sobreira G; Oliveira J; Brissos S
    Braz J Psychiatry; 2017; 39(1):86. PubMed ID: 28273272
    [No Abstract]   [Full Text] [Related]  

  • 11. Vortioxetine (Brintellix) for depression.
    Med Lett Drugs Ther; 2013 Nov; 55(1430):93-5. PubMed ID: 24276501
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
    Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
    CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vortioxetine for the treatment of major depressive disorder.
    Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
    Al-Sukhni M; Maruschak NA; McIntyre RS
    Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database.
    Subeesh V; Singh H; Maheswari E; Beulah E
    Asian J Psychiatr; 2017 Dec; 30():152-156. PubMed ID: 28942181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.
    Naik H; Chan S; Vakilynejad M; Chen G; Loft H; Mahableshwarkar AR; Areberg J
    Basic Clin Pharmacol Toxicol; 2016 May; 118(5):344-55. PubMed ID: 26525043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety.
    Greenblatt DJ; Harmatz JS; Chow CR
    J Clin Psychopharmacol; 2018 Jun; 38(3):172-179. PubMed ID: 29596146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
    Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
    Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.